<DOC>
	<DOCNO>NCT00985621</DOCNO>
	<brief_summary>The purpose study test efficacy safety 2 dos tanezumab compare oxycodone CR placebo patient osteoarthritis</brief_summary>
	<brief_title>Tanezumab In Osteoarthritis Of The Hip Or Knee</brief_title>
	<detailed_description>This study terminate 13 Dec 2010 follow US FDA clinical hold tanezumab osteoarthritis clinical study halt dose enrollment patient 23 June 2010 potential safety issue .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>osteoarthritis knee hip accord KellgrenLawrence xray grade 2 pregnancy intent become pregnant BMI great 39 severe pain , significant cardiac , neurological psychiatric disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>monoclonal antibody</keyword>
	<keyword>RN624</keyword>
	<keyword>PF-04383119</keyword>
	<keyword>nerve growth factor</keyword>
	<keyword>OA</keyword>
	<keyword>pain</keyword>
	<keyword>arthritis</keyword>
</DOC>